Edition:
United Kingdom

Cellectar Biosciences Inc (CLRB.OQ)

CLRB.OQ on NASDAQ Stock Exchange Capital Market

1.16USD
16 Feb 2018
Change (% chg)

$-0.05 (-4.13%)
Prev Close
$1.21
Open
$1.23
Day's High
$1.23
Day's Low
$1.16
Volume
52,583
Avg. Vol
44,013
52-wk High
$3.06
52-wk Low
$1.07

Latest Key Developments (Source: Significant Developments)

Cellectar Biosciences On Jan 3, Notified Affected Employees Of Its Plan To Reduce Its Workforce By 6 Positions
Monday, 8 Jan 2018 

Jan 8 (Reuters) - Cellectar Biosciences Inc ::CELLECTAR BIOSCIENCES - ON JAN 3, NOTIFIED AFFECTED EMPLOYEES OF ITS PLAN TO REDUCE ITS WORKFORCE BY 6 POSITIONS -SEC FILING.CELLECTAR BIOSCIENCES-TO RECORD NON-CASH EXPENSES OF ABOUT $1.2 MILLION IN QUARTER ENDED DEC 31 & CASH COSTS OF ABOUT $0.2 MILLION IN 2018, RELATING TO SHUTDOWN.CELLECTAR BIOSCIENCES - IN JAN 2018, CO BEGAN IMPLEMENTING SHUTDOWN OF ITS MANUFACTURING OPERATIONS AT CO'S HEADQUARTERS IN MADISON, WISCONSIN.  Full Article

Cellectar Announces Expansion of Relapsed/Refractory Multiple Myeloma Cohort In Phase 2 Trial of CLR 131
Wednesday, 6 Dec 2017 

Dec 6 (Reuters) - Cellectar Biosciences Inc ::CELLECTAR ANNOUNCES EXPANSION OF RELAPSED/REFRACTORY MULTIPLE MYELOMA COHORT IN PHASE 2 TRIAL OF CLR 131.CELLECTAR BIOSCIENCES - WILL INCREASE TARGETED PATIENT ENROLLMENT IN R/R MULTIPLE MYELOMA COHORT OF CO'S CURRENTLY ENROLLING CLR 131 PHASE 2 CLINICAL TRIAL.  Full Article

Cellectar Biosciences posts Q3 loss of $0.26 per share
Thursday, 9 Nov 2017 

Nov 9 (Reuters) - Cellectar Biosciences Inc :Cellectar Biosciences reports third quarter 2017 financial and corporate performance.Q3 loss per share $0.26.Cash and cash equivalents as of September 30, 2017 were about $5.7 million​.  Full Article

Cellectar updates median overall survival from phase 1 trial in advanced multiple myeloma
Tuesday, 7 Nov 2017 

Nov 7 (Reuters) - Cellectar Biosciences Inc ::Cellectar announces updated median overall survival of 26.2 months from cohort 1 of clr 131 phase 1 trial in advanced multiple myeloma.  Full Article

Cellectar Biosciences gets additional patent for CLR 131, CLR 125 in Japan
Tuesday, 17 Oct 2017 

Oct 17 (Reuters) - Cellectar Biosciences Inc :Cellectar Biosciences receives additional Japanese patent for CLR 131 and CLR 125 for the treatment of various solid tumors.Japanese patent office granted it a patent covering both composition of matter and method of use for CLR 131 and CLR 125​.  Full Article

Cellectar Biosciences and Pierre Fabre extend collaboration
Tuesday, 10 Oct 2017 

Oct 10 (Reuters) - Cellectar Biosciences Inc :Cellectar Biosciences and Pierre Fabre extend collaboration for development of new phospholipid drug conjugates.Cellectar Biosciences - ‍aim of extension is to further evaluate synergistic effects observed when Cellectar's phospholipid ethers are combined with Pierre Fabre's novel cytotoxic payloads​.Cellectar Biosciences - ‍program teams will continue to evaluate the new PDC compounds.  Full Article

Cellectar Biosciences says USPTO grants patent for Paclitaxel PDC
Monday, 12 Dec 2016 

Cellectar Biosciences Inc : Cellectar Biosciences announces USPTO grants patent for Paclitaxel PDC; provides additional patent protection for select solid tumors through 2035 .Cellectar Biosciences - plan to initiate a Phase II trial for CLR 131 in patients with relapsed or refractory multiple myeloma and select hematologic malignancies in early 2017.  Full Article

Cellectar Biosciences files for mixed shelf of upto $10 mln
Friday, 28 Oct 2016 

Cellectar Biosciences Inc - :Files for a mixed shelf of upto $10 million - SEC filing.  Full Article

Cellectar Biosciences announces recent key accomplishments, Q2 results
Thursday, 11 Aug 2016 

Cellectar Biosciences Inc : Cellectar Biosciences announces recent key accomplishments and second quarter 2016 financial results . Cellectar Biosciences Inc says company expects that additional capital will be required to complete its planned clinical and preclinical development .Cellectar Biosciences Inc says company estimates that its available cash and cash equivalents should fund its planned operations into Q1 of 2017.  Full Article

Cellectar Biosciences files for resale of 300,006 shares
Friday, 17 Jun 2016 

Cellectar Biosciences Inc :Files for resale of 300,006 shares of common stock offered by selling stockholders - SEC filing.  Full Article

BRIEF-Cellectar Receives USPTO Notice Of Allowance For Patent Covering Use Of CLR 131 In Multiple Myeloma

* CELLECTAR RECEIVES USPTO NOTICE OF ALLOWANCE FOR PATENT COVERING USE OF CLR 131 IN MULTIPLE MYELOMA Source text for Eikon: Further company coverage: